Electroluminescent TCC, C3dg and fB/Bb epitope assays for profiling complement cascade activation in vitro using an activated complement serum calibration standard.
暂无分享,去创建一个
A. M. Shaw | T. Mollnes | T E Mollnes | A M Shaw | B Jansen van Vuuren | G Bergseth | G. Bergseth | G. Bergseth | B. J. van Vuuren | B. V. Vuuren | T. E. Mollnes | Andrew M. Shaw
[1] G. Kuchel,et al. ELISA and multiplex technologies for cytokine measurement in inflammation and aging research. , 2008, The journals of gerontology. Series A, Biological sciences and medical sciences.
[2] C. Vedeler,et al. Systemic complement activation following human acute ischaemic stroke , 2004, Clinical and experimental immunology.
[3] Z. Prohászka,et al. Activation of the complement system in normal pregnancy and preeclampsia. , 2010, Molecular immunology.
[4] I. Brewis. The human plasma proteome , 2006 .
[5] Bo Nilsson,et al. An international serum standard for application in assays to detect human complement activation products. , 2013, Molecular immunology.
[6] T. Hugli,et al. Possible mechanism for in vitro complement activation in blood and plasma samples: futhan/EDTA controls in vitro complement activation. , 1999, Clinical chemistry.
[7] O. Attrée,et al. Comparison of electrochemiluminescence assay and ELISA for the detection of Clostridium botulinum type B neurotoxin. , 2005, Journal of immunological methods.
[8] Bo Nilsson,et al. Complement analysis in the 21st century. , 2007, Molecular immunology.
[9] C. Hack,et al. Complement activation in patients with sepsis is in part mediated by C-reactive protein. , 1998, The Journal of infectious diseases.
[10] M. Oppermann,et al. Complement activation in septic baboons detected by neoepitope‐specific assays for C3b/iC3b/C3c, C5a and the terminal C5b‐9 complement complex (TCC) , 1993, Clinical and experimental immunology.
[11] L. Truedsson,et al. Complement deficiencies and systemic lupus erythematosus , 2007, Autoimmunity.
[12] S. Frøland,et al. Quantification of the Terminal Complement Complex in Human Plasma by an Enzyme‐Linked Immunosorbent Assay Based on Monoclonal Antibodies against a Neoantigen of the Complex , 1985, Scandinavian journal of immunology.
[13] E. Brown,et al. Complement activation. , 1981, Immunology today.
[14] J. G. van der Hoeven,et al. The complement system is activated in a biphasic pattern after coronary artery bypass grafting. , 2010, The Annals of thoracic surgery.
[15] W. van Oeveren,et al. Complement activation in coronary artery bypass grafting patients without cardiopulmonary bypass: the role of tissue injury by surgical incision. , 1999, Chest.
[16] J. Köhl,et al. Re-evaluation of the storage conditions for blood samples which are used for determination of complement activation. , 1995, Journal of immunological methods.
[17] N. Hotta,et al. Complement activation products in the urine from proteinuric patients. , 1998, Journal of the American Society of Nephrology : JASN.
[18] N. Anderson,et al. The Human Plasma Proteome , 2002, Molecular & Cellular Proteomics.
[19] J. Tschopp,et al. A unique epitope exposed in native complement component C9 and hidden in the terminal SC5b-9 complex enables selective detection and quantification of non-activated C9. , 1987, Journal of immunological methods.
[20] G. Schoenhals,et al. The human plasma proteome: A biomarker pool too deep to explore? , 2006 .
[21] A. Familian,et al. Complement activation in patients with rheumatoid arthritis mediated in part by C-reactive protein. , 2001, Arthritis and rheumatism.
[22] M. Harboe,et al. The quantitative role of alternative pathway amplification in classical pathway induced terminal complement activation , 2004, Clinical and experimental immunology.
[23] R. Schreiber,et al. Initiation of the alternative pathway of complement: recognition of activators by bound C3b and assembly of the entire pathway from six isolated proteins. , 1978, Proceedings of the National Academy of Sciences of the United States of America.
[24] O. Mellbye,et al. Complement activation in rheumatoid arthritis evaluated by C3dg and the terminal complement complex. , 1986, Arthritis and rheumatism.
[25] M. Walport,et al. The Complement Factsbook , 1999 .
[26] P. Thullier,et al. Comparison of an electrochemiluminescence assay in plate format over a colorimetric ELISA, for the detection of ricin B chain (RCA-B). , 2007, Journal of immunological methods.
[27] J. Tschopp,et al. Antigenic crossreactivity of the alpha subunit of complement component C8 with the cysteine-rich domain shared by complement component C9 and low density lipoprotein receptor. , 1986, Proceedings of the National Academy of Sciences of the United States of America.
[28] J. Tschopp,et al. Monoclonal Antibodies Recognizing a Neoantigen of Poly(C9) Detect the Human Terminal Complement Complex in Tissue and Plasma , 1985, Scandinavian journal of immunology.
[29] S. Sereika,et al. Sensitivity and specificity of plasma and urine complement split products as indicators of lupus disease activity. , 1996, Arthritis and rheumatism.
[30] W. P. Reed,et al. Classical and alternative complement pathway activation by pneumococci , 1977, Infection and immunity.
[31] S. Abramson,et al. Complement activation during systemic lupus erythematosus. C3a and C5a anaphylatoxins circulate during exacerbations of disease. , 1986, Arthritis and rheumatism.